×

Stocks Novartis AG

  • With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.

  • Roche Holding said Thursday its CEO will step down next March as the pharmaceutical company separates that job from the chairman's position. It also posted a 24% increase in first-half net profit.

  • Novartis cut its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.

  • Nestle, the world's largest food company, will raise prices, cull unprofitable products and speed up production rationalization to prepare for a lasting rise in commodity and energy prices.

  • Roche has signed a deal worth up to $1 billion with Alnylam Pharmaceuticals, giving it access to the U.S. firm's skills in the new science of silencing genes to fight disease.

  • Swiss drugmaker Novartis said Wednesday it has received European Union approval for flu vaccine Optaflu.

  • It’s slim pickings in the sector, but there are a couple of stocks that are actually worth buying, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • graphic_fast_money.jpg

    What’s the biggest event of the year for biotech and big pharma? It’s the 43rd ASCO Annual Meeting where drug companies present new research that could indicate whether their cancer drugs are blockbusters or duds. It starts this Friday night in Chicago - what should you expect?

  • Severe kidney failure and some deaths have been reported in patients using Novartis's iron overload drug Exjade, the Food and Drug Administration said.

  • The market may see a Democratic congress (and possibly the White House in 2008) as detrimental to health care stocks -- but Henssler Financial Group's Ted Parrish begs to disagree. Parrish, the co-portfolio manager of the firm's Henssler Equity Fund joined "Squawk on the Street" to tout the opportunities in health care companies -- and name his favorites.

  • Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.

  • A new study offers the millions of people who have osteoporosis the hope of taking a drug to treat it only once a year. The New England Journal of Medicine reports that patients who got a once-a-year infusion of the Novartis drug Reclast saw a 70% reduction in the risk of spinal fractures and a 40% drop in the risk of hip fractures.

  • Several other major drug companies were apparently interested in buying MedImmune, including Merck, Eli Lilly and possibly Novartis, CNBC’s David Faber reported Tuesday.

  • Stocks closed lower as cautious comments from GM and Pfizer snapped the Dow's seven-day winning streak. "We've seen a really good move in the market and a little consolidation is healthy," said Bill Nichols, managing director of equity trading for Bear Stearns. "After being higher so much, a little profit-taking is only natural."

  • Strong sales of its flagship drugs boosted net profit at Swiss drugmaker Novartis by 11% to $2.171 billion, the group said on Monday, confounding expectations for a weaker profit.

  • cat_w_vet.jpg

    Health care and insurance are two of the fastest-growing segments of the booming pet market. And big drug makers such as Pfizer, Novartis and Eli Lilly have taken note.

  • The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.

  • Stocks closed with broad gains as investors bought up large cap stocks, shrugging off a 3% gain in oil prices. "People are looking for a little bit of value, particularly in the large cap sector," said Dan McMahon, head of listed trading at CIBC World Markets. "It's not a huge move but we stopped the bleeding today."

  • Here are today's trivia questions for the Bonus Bucks. They're certainly worth the "effort" and add to your portfolio. The video question is worth $2,000 bonus bucks: Which of the following is NOT a feature of a $350 million complex being built in Dubai? Answers: Office space OR 360-degree rotating floors OR Hotel rooms OR 78 stories?